Pacira Announces New Data Supporting Clinical And Pharmacoeconomic Utility Of EXPAREL In Patients Undergoing Various Surgical Procedures

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced data from three studies evaluating the clinical and pharmacoeconomic utility of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain control in patients undergoing colorectal surgery, breast reconstruction and total knee replacement surgery. The data were presented this month at the annual meetings of the World Congress of Enhanced Recovery after Surgery and Perioperative Medicine, Plastic Surgery Research Council (PSRC) and International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC